On April 20, Nanjing Hengenix Biotech Co., Ltd. successfully navigated the Hong Kong Stock Exchange (HKEX) listing hearing, with Goldman Sachs and CICC acting as its joint sponsors. The company is dedicated to the research and development of anticancer treatments leveraging synthetic lethality mechanisms, boasting a pipeline of 12 drug candidates. Notably, its flagship product, Senaparib, has secured approval for first-line maintenance therapy in ovarian cancer and is now available nationwide. The remaining 11 in-house drug candidates encompass a diverse array of clinical and preclinical projects, spanning various innovative therapeutic approaches.

Hengenix Biotech primarily generates revenue through out-licensing agreements and direct drug sales. In the previous year, the company's revenue surged by 14% year-on-year, reaching RMB 38.251 million. However, its net loss also expanded by 16%, amounting to RMB 295 million. Specifically, Senaparib recorded sales revenue of RMB 7.2 million in the first half of 2025 and RMB 20.2 million for the entire year, accompanied by an impressive gross profit margin of 92.2%.